trending Market Intelligence /marketintelligence/en/news-insights/trending/1uBV2lQVkL83bVD34K26hA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bausch Health settles class-action suit over legacy management issues for $1.21B

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Bausch Health settles class-action suit over legacy management issues for $1.21B

Bausch Health Cos. Inc. — formerly Valeant Pharmaceuticals — has agreed to pay $1.21 billion to settle a New Jersey class-action lawsuit alleging that the company failed to warn investors amid a drastic drop in share price beginning in 2015.

SNL Image

Bausch Health CEO Joseph Papa

Source: Bausch Health

Shares of Valeant fell from more than $250 in 2015 to under $9 two years later after lawmakers questioned why the price of drugs acquired by the company had more than quadrupled.

In a class-action lawsuit filed in the U.S. District Court of New Jersey, plaintiffs claimed that Valeant executives were liable for making false statements or failing to disclose facts about the company that led to the downfall. Investors argued that the actions caused them to purchase Valeant stock at inflated prices.

The case remained in court through a turnaround effort at Valeant, in which CEO Joseph Papa was brought on and a change of name to Bausch Health was executed. The name came from one of the companies previously acquired by Valeant, eyecare specialist Bausch & Lomb.

The settlement fully resolves the case, according to a Dec. 16 press release from Bausch Health. The company admitted no liability and denied all wrongdoing.

"Resolving this action enables Bausch Health to close the door on one of the more meaningful and unpredictable liabilities associated with the legacy Valeant era," Papa said in a statement. "The settlement of this case removes a cloud of uncertainty and ensures that current and future stakeholders will enjoy the benefits of the ongoing transformation of Bausch Health."

S&P Global Ratings upgraded Bausch Health's credit rating to B+ from B on the news, saying the credit quality is enhanced by a reduction in uncertainty.

"We also believe that Bausch Health's management team, in place since 2016, has made significant progress in resolving legacy management and governance issues from prior management, as well as firmly restoring the company to growth," Ratings said in a Dec. 16 report.

Meanwhile, Moody's Investors Service said the settlement was credit negative because the $1.21 billion represented about one year of Bausch Health's free cash flow, impeding the company's ongoing deleveraging. The agency did not change the credit rating, however.

Bausch Health will begin paying the settlement in mid-January 2020, and the payment will not affect the current 2019 financial guidance.

This S&P Global Market Intelligence news article may contain information about credit ratings issued by S&P Global Ratings. Descriptions in this news article were not prepared by S&P Global Ratings.